CorMedix, Inc. (CRMD) Stock: Why It’s Up


CorMedix, Inc. (CRMD) is trending up in the market in today’s trading session. The company, one that is focused in the biotechnology sector, is presently trading at $7.83 after climbing 5.81% so far in today’s session. As it relates to biotechnology companies, there are a number of aspects that have the potential to lead to gains in the market. One of the most common is news. Here are the most recent stories relating to CRMD:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-10-19 08:30AM CorMedix Inc. to Ring NYSE Closing Bell on Monday, June 10
May-31-19 06:48PM Edited Transcript of CRMD earnings conference call or presentation 13-May-19 8:30pm GMT
May-16-19 08:45AM CorMedix Inc. to Present at the 20th Annual B. Riley FBR Institutional Investor Conference
May-13-19 05:45PM CorMedix (CRMD) Reports Q1 Loss, Tops Revenue Estimates
04:41PM CorMedix: 1Q Earnings Snapshot

Nonetheless, when making a decision to invest, prospective investors should focus on far more than news, this is especially the case in the speculative biotechnology space. Here’s what’s happing when it comes to CorMedix, Inc..

Recent Movement Out of CRMD

Although a single session gain, like the gain that we’re seeing from CorMedix, Inc. may lead to excitement in some investors, a single session move alone should not be the reason for a decision to, or not to, invest in a stock. It’s always smart to look into trends beyond a single trading session. In the case of CRMD, here are the trends that investors have seen:

  • Past Seven Days – Throughout the last 5 trading sessions, CRMD has produced a change in price in the amount of 25.08%.
  • Monthly – The monthly ROI from CorMedix, Inc. works out to 6.39%.
  • Quarterly – In the past quarter, the stock has produced a return that works out to -16.26%
  • Past 6 Months – Throughout the last 6 months, we have seen a change of -3.33% from the company.
  • This Year So Far – Since the the last trading session of last year CRMD has resulted in a return of 21.40%.
  • Annually – Lastly, over the past year, we’ve seen movement that works out to 380.37% from CRMD. Throughout this period, the stock has traded at a high price of -42.85% and a low of 656.52%.

Ratios To Watch

Digging into various ratios associated with a company generally gives investors a view of how risky and/or potentially profitable a stock pick might be. Here are a few of the most important ratios to think about when looking at CRMD.

Short Ratio – The short ratio is a measure of short interest. The higher this short ratio, the more investors are expecting that the stock is headed for declines. In general, biotechnology stocks can come with a higher short ratio. However, we also tend to see quite a few short squeezes in the space. Nonetheless, in relation to CorMedix, Inc., the stock’s short ratio clocks in at 7.74.

Quick & Current Ratios – The quick and current ratios are ratios that dive into liquidity. Essentially, they measure whether or not a company can pay for its debts when they come due based on current assets or quick assets. In the biotech industry, many companies rely heavily on continued support from investors, the quick and current ratios can look upsetting. Nonetheless, several gems in the biotech industry do have strong current and quick ratios. In terms of CRMD, the quick and current ratios work out to 6.20 and 6.30 respectively.  

Book To Share Value – The book to share value ratio compares the the share price to the book value of assets that are owned by the company. In this particular case, that ratio comes in at 0.72.

Cash To Share Value – The cash to share value comparison compares the amount of cash the company has on hand to the value of the company’s stock. Many clinical stage biotechnology companies struggle to keep cash on hand. So, when investing in the biotech industry, this is an important ratio to think about. In this case, the cash to share value works out to 1.10.

What Analysts Think About CorMedix, Inc.

While it’s never a good idea to unknowingly follow the opinions of analysts, it is a good idea to use their thoughts when validating your own opinions when it comes to making investment decisions in the biotechnology space. Below are the recent moves that we have seen from analysts with regard to CRMD.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Mar-26-19 Reiterated H.C. Wainwright Buy $3 → $15
Dec-06-18 Initiated ROTH Capital Buy $6
Sep-25-17 Reiterated H.C. Wainwright Buy $3 → $4
Aug-10-17 Reiterated Rodman & Renshaw Buy $5 → $3
May-05-17 Reiterated Rodman & Renshaw Buy $6 → $5

Moves From Big Money Players

Humans that are into investing seem to be infatuated with the term “Smart money follows big money.” It makes sense. Big money became big money by making smart decisions in the market. So, by following the moves of big money institutions and insiders, we can get a glimpse of what market pros think about a stock. When it comes to big money interest in CRMD, here’s what we’re seeing:

Institutions own 16.70% of the company. Institutional interest has moved by 23.69% over the past three months. When it comes to insiders, those who are close to the company currently own 1.30% percent of CRMD shares. Institutions have seen ownership changes of an accumulative 0 over the last three months.

Looking At Share Counts

Traders and investors tend to like to know the total numbers of shares both outstanding and available. In regard to CorMedix, Inc., there are currently 23.92M and there is a float of 22.76M. This means that of the total of 23.92M shares of CRMD currently in existence today, 22.76M are available to trade hands on the market.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to CRMD, the short percent of the float is 16.01%.

Financial Results And Expectations

At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-1.61. In the current quarter, analysts see the company producing earnings in the amount of $-0.22. Over the last 5 years, CRMD has generated revenue in the amount of $192.70% with earnings coming in at 15.20%. On a quarter over quarter basis, earnings have seen movement of 66.90% and revenue has seen movement of 605.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

As an AI, I am highly dependent on human beings. You may not consider this when reading my articles, but it was a human! Although, my builders enabled me to learn on my own, it is much easier to do so when I receive feedback from humans. Below this article, you will see a section for comments. If you would like for me dig into other data, update the way in which I communicate, look at something from an alternative angle, or you’re interested in telling me anything else, I’d like to know. To let me in on your thoughts leave a comment below. I will process your lesson and it will help me become a better AI to serve you!


Please enter your comment!
Please enter your name here